The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Biomarkers of Lupus Disease Study

The Biomarkers of Lupus Disease Study

May 31, 2017 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Objective: Molecular medicine raised expectations for strategically targeted biologic agents in systemic lupus erythematosus (SLE), but clinical trials have been disappointing and difficult to interpret. Most studies add investigational agents to various, often effective, standard therapy immunosuppressants used at baseline, with unknown treatment interactions. Eliminating polypharmacy in trials of active lupus remains controversial. The authors undertook the “Biomarkers of Lupus Disease Study” to test the withdrawal of immunosuppressants as a novel approach to rendering SLE trials interpretable.

You Might Also Like
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
  • Plasmabast Responses Provide a Signature for Lupus Disease Activity
  • New Study Examines Pregnancy Risk Factors for Patients with Lupus

Methods: Temporary steroids were given to a group of 41 patients with active, non-organ-threatening SLE flare (group A) while background immunosuppressants were withdrawn. Time to loss of disease suppression (flare) and safety were evaluated. Standard therapy was immediately resumed when symptoms recurred. The immunologic impacts of standard therapy were studied at baseline by multiplex assay, enzyme-linked immuno-sorbent assay and messenger RNA array in both group A patients and 62 additional patients who donated a single sample (group B).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Patients with lower or higher baseline disease activity had median times to flare of 71 or 45 days, respectively; 40 of 41 patients (98%) had disease flares by six months. All flares were treated and resolved within six weeks. No serious adverse events occurred from flare or infection. Type I interferon (IFN), Th17 and B lymphocyte stimulator pathways tracked together. Baseline immunosuppressants had distinct impacts on Th17 and B lymphocyte stimulator, depending on IFN signature.

Conclusion: Trials in active, non-organ-threatening SLE can safely withdraw background treatments if patients who have disease flares are designated nonresponders and returned to standard therapy. Immunologic effects of standard therapy vary between IFN-defined subsets. These findings provide a strategy for minimizing or optimizing treatment combinations in lupus trials and clinical care.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Read the full article.

Excerpted and adapted from:
Merrill JT, Immermann F, Whitley M, et al. The biomarkers of lupus disease study: A bold approach may mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol. 2017 Jun;69(6):1257–1266.

Filed Under: Conditions, SLE (Lupus) Tagged With: Arthritis & Rheumatology, Biomarker, Biomarkers, Lupus, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
  • Plasmabast Responses Provide a Signature for Lupus Disease Activity
  • New Study Examines Pregnancy Risk Factors for Patients with Lupus
  • New Study Examines Treatment Options for Incomplete Lupus Erythematous

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.